GSM gold starGSM Global
中文版 · Chinese

Lexeo Gene Therapy LX2020 Cuts Arrhythmia Burden 80% in High-Dose Cohorts as FDA Opens Door to Accelerated Approval Path

Monday, November 16, 2026 · Health · GSM News

Lexeo Therapeutics (Nasdaq: LXEO), a New York-based clinical-stage biotechnology company, announced on November 16 that its gene therapy candidate LX2020 showed positive interim data in the HEROIC-PKP2 Phase I/II trial in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM), with a marked reduction in arrhythmia burden in the high-dose cohorts and a U.S. Food and Drug Administration (FDA) signal open to an accelerated approval pathway.

Ten participants have been dosed in the trial, including three in the low-dose cohort and seven in the high-dose cohorts. As of the October 15, 2026 data cutoff, nine participants had reached at least 12 months of follow-up and the remaining participant nine months. At the latest assessment, participants in the high-dose cohorts achieved an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) relative to baseline, with six of seven improving, and a 44% mean reduction in premature ventricular contraction (PVC) burden, with five of seven improving. Cardiac MRI showed stabilization or improvement in cardiac function in the majority of high-dose participants, and cardiac biopsies showed dose-dependent increases in PKP2 protein expression.

LX2020 was generally well tolerated across the ten participants, with no clinically significant complement activation and no discontinuations. Previously disclosed elevations in liver function tests in the high-dose cohorts were treated successfully under the protocol with no complications or hospitalizations. One previously disclosed Grade 3 serious adverse event of ventricular tachycardia, observed three months after dosing, was described as consistent with the natural course of PKP2-ACM; the participant was treated with anti-arrhythmic medication and discharged with no additional intervention.

On the regulatory path, the FDA is open to the use of guideline-defined NSVT as a primary surrogate endpoint in a pivotal study supporting accelerated approval. Lexeo expects to finalize the pivotal study design, statistical analysis plan and confirmatory strategy in the first half of 2027 and to initiate the pivotal study in the second half of 2027. LX2020 has previously received Regenerative Medicine Advanced Therapy, Orphan Drug and Fast Track designations from the FDA.

Mutations in the PKP2 gene are the most common genetic cause of arrhythmogenic cardiomyopathy, accounting for about half of cases and affecting an estimated 60,000 people in the United States. LX2020 is designed to deliver a functional, full-length PKP2 gene to cardiomyocytes to address the underlying biology of the disease.

Lexeo also reported third-quarter 2026 results the same day: a net loss of $38.3 million, or $0.43 per share. As of September 30, cash, cash equivalents and investments totaled $219.1 million, which the company said is expected to fund operations into 2028.

(Source: Lexeo Therapeutics)

Source: Lexeo Therapeutics

Published by GSM · USA (original Chinese edition)

Photo: 图:美国食品药品监管局(FDA)总部大楼入口。FDA 官方图,公共领域,经 Wikimedia Commons。 / Photo: Entrance of the U.S. Food and Drug Administration headquarters. FDA official photo, public domain, via Wikimedia Commons.

Latest in Health